³í¹®) Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
¿¬¼¼´ë °³²¼¼ºê¶õ½ºº´¿ø(º´¿øÀå ¼Û¿µ±¸) À¯¹æ¿Ü°ú ¾È¼º±Í ±³¼ö, Á¾¾ç³»°ú ±èÁöÇü ±³¼ö, ±¹Á¦¼º¸ðº´¿ø À¯¹æ¿Ü°ú ÁöÁ¤È¯ ±³¼ö ¿¬±¸ÆÀ